MK8245

MK8245 Basic information
Product Name:MK8245
Synonyms:MK 8245;MK8245;5-[3-[4-(2-Bromo-5-fluorophenoxy)-1-piperidinyl]-5-isoxazolyl]-2H-tetrazole-2-acetic acid;2-(5-(3-(4-(2-broMo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid;MK8245;MK-8245;MK 8245;CS-1662;]-2H-tetrazoL;]-5-isoxazoL;5-[3-[4-(2-Bromo-5-fL
CAS:1030612-90-8
MF:C17H16BrFN6O4
MW:467.25
EINECS:
Product Categories:Inhibitors;Inhibitor
Mol File:1030612-90-8.mol
MK8245 Structure
MK8245 Chemical Properties
Boiling point 698.3±65.0 °C(Predicted)
density 1.82
storage temp. Sealed in dry,Store in freezer, under -20°C
solubility ≥23.35 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
form solid
pka2.85±0.10(Predicted)
Safety Information
MSDS Information
MK8245 Usage And Synthesis
DescriptionMK-8245 is a liver-targeted inhibitor of stearoyl-CoA desaturase (SCD; IC50s = 3, 3, and 1 nM for rat, mouse, and human SCD1, respectively). It is selective for SCD1 over Δ5- and Δ6-desaturases (IC50s = >100,000 nM). MK-8245 (20-60 mg/kg) reduces the hepatic, but not Harderian gland, ratio of oleic acid to stearic acid, a marker of chronic SCD activity, and blood glucose levels, without inducing the formation of skin lesions or eye squinting behavior, in a mouse model of high-fat diet-induced obesity. It also inhibits hepatitis C virus (HCV) replication without inducing cytotoxicity in LucNeo2 cells (IC50 = 39.8 nM).
UsesThis product is Informer compound X9 of the Aryl Halide Chemistry Informer Library developed by chemists at Merck & Co., Inc., Kenilworth, NJ, U.S., which contains 18 drug-like molecules representative of those encountered in complex synthesis. By screening a new reaction against the Informer Library, chemists can directly compare and analyse a reaction′s successes and shortcomings among different methods and various research teams. It may also be used to facilitate deeper method development for performance or utility.
targetSCD1 (human)
references[1] oballa rm, belair l, black wc, bleasby k, chan cc, desroches c, du x, gordon r, guay j, guiral s, hafey mj, hamelin e, huang z, kennedy b, lachance n, landry f, li cs, mancini j, normandin d, pocai a, powell da, ramtohul yk, skorey k, srensen d, sturkenboom w, styhler a, waddleton dm, wang h, wong s, xu l, zhang l. development of a liver-targeted stearoyl-coa desaturase (scd) inhibitor (mk-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. j med chem. 2011 jul 28;54(14):5082-96.
[2] lachance n, guiral s, huang z, leclerc jp, li cs, oballa rm, ramtohul yk, wang h, wu j, zhang l. discovery of potent and liver-selective stearoyl-coa desaturase (scd) inhibitors in an acyclic linker series. bioorg med chem lett. 2012 jan 1;22(1):623-7.
Canertinib Olaparib MG-132 ABT-199 Conivaptan hydrochloride PI-103

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.